The yin and yang of interleukin-2-mediated immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Regulatory T cells in primary sjögren disease: regulatory mechanisms and therapeutic prospects.Frontiers in immunology · 2026
   Review
2. A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant.Frontiers in immunology · 2024
   Article
3. Low Dose Interleukin-2 Ameliorates Sjögren's Syndrome in a Murine Model.Frontiers in medicine · 2022
   Article
4. Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction.Cancers · 2020
   Review
5. Increased Serum Interleukin-2 Levels Are Associated with Abnormal Peripheral Blood Natural Killer Cell Levels in Patients with Active Rheumatoid Arthritis.Mediators of inflammation · 2020
   Article
6. Prospects of IL-2 in Cancer Immunotherapy.BioMed research international · 2018
   Review
7. In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.Cancer immunology, immunotherapy : CII · 2017
   Article
8. CCR8Proceedings of the National Academy of Sciences of the United States of America · 2017
   Article
9. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.Oncotarget · 2015
   Article
10. Tuning IL-2 signaling by ADP-ribosylation of CD25.Scientific reports · 2015
    Article
11. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
12. Inducing and Administering Tregs to Treat Human Disease.Frontiers in immunology · 2015
    Review
13. Inhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cells.PloS one · 2015
    Article
14. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells.Journal of immunology (Baltimore, Md. : 1950) · 2014
    Article
15. Targeting regulatory T cells in cytokine-induced killer cell cultures (Review).Biomedical reports · 2014
    Article
16. Homeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic Tregs.Immunological reviews · 2014
    Review
17. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Expert review of clinical immunology · 2014
    Review
18. Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.BioMed research international · 2014
    Article
19. Regulatory T-cell therapy in transplantation: moving to the clinic.Cold Spring Harbor perspectives in medicine · 2013
    Review
20. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus.Arthritis and rheumatism · 2013
    Article

Corrections and comments

• Comment on
  Interleukin-2 and regulatory T cells in graft-versus-host disease.2011
• Comment on
  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.2011

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as